Professor Susan Branford

Adjunct Professor Centre for Cancer Biology

City West Campus (HB8-26)
tel +61 8 830 27730

email Susan.Branford@unisa.edu.au

Research Degree Supervisor

Research

Research focus

Cardiovascular Medicine and Haematology
Clinical Sciences
Oncology and Carcinogenesis
Biochemistry and Cell Biology
Medical Microbiology

Research

Outputs

Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID

Open access indicates that an output is open access.

Chapters

Year	Output
2021	Branford, S, Shanmuganathan, N & Hughes, TP 2021, 'Response-related predictors of survival and of treatment-free remission in CML', in R Hehlmann (ed.), Chronic Myeloid Leukemia, Springer, Switzerland, ch. 15, pp. 245-264. Open access
2015	Yeung, DT & Branford, S 2015, 'Optimal monitoring of CML treatment: molecular and mutation analysis', in Masahiro Kizaki (ed.), Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia, Springer, Japan, ch.7, pp. 101-129.

Journal Articles

Year	Output
2025	Metzler, M, Branford, S, Hijiya, N & Sakamoto, K 2025, 'Old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia', British Journal of Haematology, online, pp. 1-7.
2025	Toubia, J, Kusay, Y, Maqsood, M, Warnock, N I, Lawrence, DM, Bracken, CP, Gregory, PA, Kan, WL, Selth, LA, Conn, SJ, Lopez, AF, Branford, S, Scott, HS, Kok, CH, Goodall, GJ & Schreiber, AW 2025, 'TRanscriptome ANalysis of StratifiEd CohorTs (TRANSECT) enables automated assessment of global gene regulation linked to disparate expression in user defined genes and gene sets', NAR Genomics and Bioinformatics, vol. 7, no. 2, article no. lqaf041, pp. 1-13. Open access
2024	Branford, S, Fernandes, A, Shahrin, NH, Maqsood, M, Shanmuganathan, N & Wadham, C 2024, 'Beyond BCR::ABL1-the role of genomic analyses in the management of CML', Journal of the National Comprehensive Cancer Network, vol. 22, no. 1, pp. 1-9. Open access
2024	Hong, LE, Wechalekar, MD, Kutyna, M, Small, A, Scott, HS, Brown, A, Hahn, CN, Robinson, N, Branford, S, D'Andrea, RJ, Samaraweera, SE, Kok, CH & Hiwase, DK and 13 other authors 2024, 'IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation', Blood, vol. 143, no. 18, pp. 1873-1877. 33
2024	Kockerols, C, Valk, PJ, Dulucq, S, Nicolini, FE, Branford, S & Westerweel, PE and 17 other authors 2024, 'BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: an individual participant data meta-analysis', American Journal of Hematology, vol. 99, no. 8, pp. 1632-1635. Open access
2024	Kok, CH, Irani, Y, Clarson, J, Saunders, V, Dang, P, Shanmuganathan, N, Branford, S, Yeung, D, Yong, AS & Hughes, TP 2024, 'CD302 predicts achievement of deep molecular response in chronic myeloid leukemia patients treated with imatinib', Blood Neoplasia, vol. 1, no. 2, article no. 100014, pp. 1-11. Open access
2024	Yeung, DT, Shanmuganathan, N, Reynolds, J, Branford, S & Hughes, TP 2024, 'Asciminib Monotherapy as frontline treatment of chronic-phase chronic Myeloid Leukemia: results from the ASCEND Study', Blood, vol. 144, no. 9, pp. 1993-2001.
2024	Zerella, JR, Homan, CC, Arts, P, Lin, X, Spinelli, SJ, Venugopal, P, Babic, M, Brautigan, PJ, Arriola-Martinez, L, Parker, WT, Branford, S, Ross, DM, Brown, AL, Scott, HS & Hahn, CN 37 other authors and 1 consortium 2024, 'Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition', Blood, vol. 144, no. 17, pp. 1765-1780. Open access 23
2023	Irani, YD, Hughes, A, Kok, CH, Clarson, J, Yeung, DT, Ross, DM, Branford, S, Hughes, TP & Yong, AS 2023, 'Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha', British Journal of Haematology, vol. 202, no. 6, pp. 1127-1136.
2023	Irani, YD, Kok, CH, Clarson, J, Shanmuganathan, N, Branford, S, Yeung, DT, Ross, DM, Hughes, TP & Yong, AS 2023, 'Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia', Blood Advances, vol. 7, no. 11, pp. 2364-2374. Open access
2023	Kok, CH, Saunders, VA, Dang, P, Shanmuganathan, N, White, D, Branford, S, Yeung, D & Hughes, TP 2023, 'Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib', Blood Cancer Journal, vol. 13, no. 1, pp. 1-9. Open access
2023	Pagani, IS, Shanmuganathan, N, Dang, P, Saunders, VA, Grose, R, Kok, CH, James, J, Tolland, M, Braley, JA, Altamura, HK, Yeung, DT, Branford, S, Yong, AS, Hughes, TP & Ross, DM 2023, 'Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy', Blood, vol. 142, no. 25, pp. 2192-2197. Open access
2023	Shanmuganathan, N, Wadham, C, Shahrin, NH, Feng, J, Thomson, D, Wang, P, Kok, CH, King, RM, Kenyon, RR, Lin, M, Ross, DM, Yeung, DT, Scott, HS, Schreiber, AW & Branford, S and 9 other authors 2023, 'Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention', Haematologica: The Hematology Journal, vol. 108, no. 9, pp. 2380-2395. Open access 15
2022	Adnan Awad, S, Brück, O, Shanmuganathan, N, Jarvinen, T, Lähteenmäki, H, Klievink, J, Ibrahim, H, Kytölä, S, Koskenvesa, P, Hughes, TP, Branford, S, Kankainen, M & Mustjoki, S 2022, 'Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation', Blood Cancer Journal, vol. 12, no. 4, article no. 69. Open access
2022	Arber, DA, Orazi, A, Hasserjian, RP, Borowitz, MJ, Branford, S & Tefferi, A 2022, 'International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data', Blood, vol. 140, no. 11, pp. 1200-1228. Open access
2022	Branford, S & Apperley, JF 2022, 'Measurable residual disease in chronic myeloid leukemia', Haematologica: The Hematology Journal, vol. 107, no. 12, pp. 2794-2809. Open access
2022	Branford, S 2022, 'Commentary on Dominy et al., assessment of quantitative PCR for BCR::ABL1 Transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?', British Journal of Haematology, vol. 197, no. 1, pp. 9-10. Open access
2022	Branford, S 2022, 'Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia', Turkish Journal of Hematology, vol. 39, no. 3, pp. 204-205. Open access
2022	Fernandes, A, Shanmuganathan, N & Branford, S 2022, 'Genomic mechanisms influencing outcome in chronic myeloid leukemia', Cancers, vol. 14, no. 3, article no. 620. Open access
2022	Krishnan, V, Kim, DDH, Hughes, TP, Branford, S & Ong, ST 2022, 'Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers', Haematologica: The Hematology Journal, vol. 107, no. 2, pp. 358-370. Open access
2022	Lu, L, Kok, CH, Dang, P, Branford, S, Saunders, VA, Naranie, S, Ross, DM, Hughes, TP & Yeung, DT 2022, 'Highly sensitive droplet digital polymerase chain reaction for BCR :: ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission', British Journal of Haematology, vol. 198, no. 3, pp. 600-603. Open access
2022	Shahrin, NH, Wadham, C & Branford, S 2022, 'Defining higher-risk chronic myeloid leukemia: risk scores, genomic landscape, and prognostication', Current Hematologic Malignancy Reports, vol. 17, no. 6, pp. 171-180. Open access
2022	Shanmuganathan, N & Branford, S 2022, 'Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing', British Journal of Haematology, vol. 196, no. 1, pp. 19-30. Open access
2022	Shanmuganathan, N, Wadham, C, Thomson, D, Shahrin, NH, Vignaud, C, Obourn, V, Chaturvedi, S, Yang, F, Feng, J, Saunders, V, Kok, CH, Yeung, D, King, RM, Kenyon, RR, Lin, M, Wang, P, Scott, H, Hughes, T, Schreiber, AW & Branford, S 2022, 'RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia', Journal of Molecular Diagnostics, vol. 24, no. 7, pp. 803-822. Open access 3
2021	Adnan Awad, S, Dufva, O, Ianevski, A, Ghimire, B, Koski, J, Maliniemi, P, Thomson, D, Schreiber, A, Heckman, CA, Koskenvesa, P, Korhonen, M, Porkka, K, Branford, S, Aittokallio, T, Kankainen, M & Mustjoki, S 2021, 'RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses', Leukemia, 1-13. Open access
2021	Branford, S 2021, 'Taming the gatekeeper: ponatinib dose holds the key', Blood, vol. 138, no. 21, pp. 2011-2012. Open access
2021	Ochi, Y, Yoshida, K, Huang, Y-J, Kuo, M-C, Branford, S, Shanmuganathan, N & Shih, L-Y and 28 other authors 2021, 'Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia', Nature Communications, vol. 12, no. 1, article no. 2833, pp. 1-13. Open access
2021	Shanmuganathan, N, Pagani, IS, Ross, DM, Park, S, Yong, AS, Braley, J, Altamura, H, Hiwase, DK, Yeung, DT, Kim, D-W, Branford, S & Hughes, TP 2021, 'Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia', Blood, vol. 137, no. 9, pp. 1196-1207. Open access
2020	Branford, S 2020, 'Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?', Haematologica: The Hematology Journal, vol. 105, no. 12, pp. 2730-2737. Open access
2020	Pagani, IS, Dang, P, Saunders, VA, Braley, J, Thieleke, A, Branford, S, Hughes, TP & Ross, DM 2020, 'Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia', Leukemia and Lymphoma, vol. 61, no. 10, pp. 2527-2529. Open access
2020	Pagani, IS, Dang, P, Saunders, VA, Grose, R, Shanmuganathan, N, Kok, CH, Carne, L, Rwodzi, Z, Watts, S, McLean, J, Braley, J, Altamura, H, Yeung, DT, Branford, S, Yong, AS, White, DL, Hughes, TP & Ross, DM 2020, 'Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission', Leukemia, vol. 34, pp. 1052-1061. Open access
2020	Schmitz, U, Shah, JS, Dhungel, BP, Monteuuis, G, Luu, PL, Petrova, V, Metierre, C, Nair, SS, Bailey, CG, Saunders, VA, Turhan, AG, White, DL, Branford, S, Clark, SJ, Hughes, TP, Wong, JJ & Rasko, JE 2020, 'Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients', Cancers, vol. 12, no. 12, article no. 3738, pp. 1-19. Open access
2020	Thomson, DW, Shahrin, NH, Wang, PP, Wadham, C, Shanmuganathan, N, Scott, HS, Dinger, ME, Hughes, TP, Schreiber, AW & Branford, S 2020, 'Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia', Leukemia, vol. 34, no. 8, pp. 2051-2063. Open access 1
2019	Branford, S, Kim, DDH, Apperley, JF, Eide, CA, Mustjoki, S, Ong, ST, Nteliopoulos, G, Ernst, T, Chuah, C, Gambacorti-Passerini, C, Mauro, MJ, Druker, BJ, Kim, D-W, Mahon, F-X, Cortes, J, Radich, JP, Hochhaus, A & Hughes, TP and 1 consortia 2019, 'Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia', Leukemia, vol. 33, no. 8, pp. 1835-1850. Open access
2019	Lasica, M, Willcox, A, Burbury, K, Ross, DM, Branford, S, Butler, J, Filshie, R, Januszewicz, H, Joske, D, Mills, A, Simpson, D, Tam, C, Taylor, K, Watson, AM, Wolf, M & Grigg, A 2019, 'The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia', Leukemia and Lymphoma, vol. 60, no. 7, pp. 1796-1802. Open access
2019	Magistroni, V, Mauri, M, D'Aliberti, D, Mezzatesta, C, Branford, S & Piazza, R 2019, 'De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways', Haematologica: The Hematology Journal, vol. 104, no. 9, pp. 1789-1797. Open access
2019	Ross, DM, Pagani, IS, Irani, YD, Clarson, J, Leclercq, T, Dang, P, McLean, J, Saunders, VA, Carne, L, Reynolds, J, Ritchie, DS, White, DL, Branford, S, Hughes, TP & Yong, AS 2019, 'Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia', British Journal of Haematology, vol. 186, no. 3, pp. e56-e60. Open access
2019	Shanmuganathan, N & Branford, S 2019, 'The hidden pathogenesis of CML: is BCR-ABL1 the first event?', Current Hematologic Malignancy Reports, vol. 14, no. 6, pp. 501-506. Open access
2019	Shanmuganathan, N, Braley, JA, Yong, AS, Hiwase, DK, Yeung, DT, Ross, DM, Hughes, TP & Branford, S 2019, 'Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission', Blood, vol. 134, no. 1, pp. 85-89. Open access
2019	Shanmuganathan, N, Branford, S, Hughes, TP & Hiwase, D 2019, 'Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI', Blood Advances, vol. 3, no. 3, pp. 370-374. Open access
2019	Sharplin, K, Altamura, H, Taylor, K, Wellwood, J, Taylor, D & Branford, S 2019, 'Chronic myeloid leukaemia: the dangers of not knowing your BCR-ABL1 transcript', Leukemia Research, vol. 87, article no. 106231, pp. 1-3. Open access
2019	Singhal, D, Wee, LYA, Kutyna, MM, Chhetri, R, Schreiber, AW, Feng, J, Branford, S, D'Andrea, RJ & Hiwase, D and 18 other authors 2019, 'The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution', Leukemia, vol. 33, no.12, pp. 2842-2853. 3
2018	Branford, S, Wang, P, Yeung, DT, Thomson, D, Wadham, C, Shahrin, NH, Marum, JE, Nataren, N, Parker, WT, Shanmuganathan, N, Donaldson, Z, Altamura, H, Georgievski, J, Brown, A, Hahn, C, White, DL, Scott, HS, Schreiber, AW & Hughes, TP and 18 other authors 2018, 'Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease', Blood, vol. 132, no. 9, pp. 948-961. Open access 9
2018	Eadie, LN, Saunders, VA, Branford, S, White, DL & Hughes, TP 2018, 'The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro', Oncotarget, vol. 9, no. 17, pp. 13423-13437. Open access
2018	Hiwase, D, Tan, P, D'Rozario, J, Taper, J, Powell, A, Irving, I, Wright, M, Branford, S, Yeung, DT, Anderson, L, Gervasio, O, Levetan, C, Roberts, W, Solterbeck, A, Traficante, R & Hughes, T 2018, 'Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift study', Leukemia Research, vol. 67, pp. 109-115. Open access
2018	Pagani, IS, Dang, P, Kommers, IO, Goyne, JM, Nicola, M, Saunders, VA, Braley, J, White, DL, Yeung, DT, Branford, S, Hughes, TP & Ross, DM 2018, 'BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia', Haematologica: The Hematology Journal, vol. 103, no. 12, pp. 2026-2032. Open access
2018	Ross, DM, Pagani, IS, Shanmuganathan, N, Kok, CH, White, DL, Branford, S & Hughes, TP and 11 other authors and 1 constourium 2018, 'Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells', Leukemia, vol. 32, no. 12, pp. 2572-2579.
2017	Casolari, D, Nguyen, T, Butcher, C, Iarossi, D, Hahn, C, Bray, S, Neufing, P, Parker, W, Feng, J, Maung, K, Wee, A, Vidovic, L, Kok, C, Bardy, P, Branford, S, Lewis, I, Lane, S, Scott, H, Ross, D & D'Andrea, R 2017, 'A novel, somatic, transforming mutation in the extracellular domain of epidermal growth factor receptor identified in myeloproliferative neoplasm', Scientific Reports, vol. 7, article no. 2467, pp. 1-9. Open access 3
2017	Hochhaus, A, Larson, RA, Guilhot, F, Radich, JP, Branford, S, Hughes, TP, Baccarani, M, Deininger, MW, Cervantes, F, Fujihara, S, Ortmann, CE, Menssen, HD, Kantarjian, H, O'Brien, SG & Druker, BJ 2017, 'Long-term outcomes of imatinib treatment for chronic myeloid leukemia', New England Journal of Medicine, vol. 376, pp. 917-927. Open access
2017	Hughes, T, Leber, B, Cervantes, F, Spector, N, Pasquini, R, Clementino, N, Schwarer, A, Dorlhiac-Llacer, P, Mahon, F, Rea, D, Guerci-Bresler, A, Kamel-Reid, S, Bendit, I, Acharya, S, Glynos, T, Dalal, D, Branford, S & Lipton, J 2017, 'Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: Final ENESTcmr randomized trial results', Leukemia, vol. 31, no. 11, pp. 2529-2531. Open access
2017	Ma, L, Boucher, JI, Paulsen, J, Matuszewski, S, Eide, CA, Ou, J, Eickelberg, G, Press, RD, Zhu, LJ, Druker, BJ, Branford, S, Wolfe, SA, Jensen, JD, Schiffer, CA, Green, MR & Bolon, DN 2017, 'CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy', Proceedings of the National Academy of Sciences of USA, vol. 114, no. 44, pp. 11751-11756. Open access
2017	Marum, JE, Yeung, DT, Purins, L, Reynolds, J, Parker, WT, Stangl, D, Wang, PP, Price, DJ, Tuke, J, Schreiber, AW, Scott, HS, Hughes, TP & Branford, S 2017, 'ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure', Blood Advances, vol. 1, no. 18, pp. 1369-1381. Open access
2017	Wylie, AA, Schoepfer, J, Jahnke, W, Cowan-Jacob, SW, Branford, S & Sellers, WR and 22 other authors 2017, 'The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1', Nature, vol. 543, no. 7647, pp. 733-737. Open access
2016	Branford, S 2016, 'Molecular monitoring in chronic myeloid leukemia - How low can you go?', Hematology, vol. 2016, no. 1, pp. 156-163. Open access
2016	Branford, S 2016, 'Monitoring and defining early response: where to draw the line?', Best Practice and Research: Clinical Haematology, vol. 29, no. 3 pp. 284-294.
2016	Cross, N, White, H, Ernst, T, Welden, L & Branford, S and 51 other authors 2016, 'Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale', Leukemia, vol. 30, no. 9, pp. 1844-1852. Open access
2016	Deininger, MW, Hodgson, JG, Shah, NP, Cortes, JE & Branford, S and 16 other authors 2016, 'Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients', Blood, vol. 127, no. 6, pp. 703-712. Open access
2016	Latham, S, Bartley, PA, Budgen, B, Ross, DM, Hughes, E, Branford, S, White, D, Hughes, TP & Morley, AA 2016, 'BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia', Journal of Clinical Pathology - Clinical Molecular Pathology, vol. 69, no. 9, pp. 817-821.
2016	Marum, JE & Branford, S 2016, 'Current developments in molecular monitoring in chronic myeloid leukemia', Therapeutic Advances in Hematology, vol. 7, no. 5, pp. 237-251. Open access
2016	Parker, WT, Yeung, DT, Yeoman, AL, Altamura, HK, Jamison, BA, Field, CR, Hodgson, JG, Lustgarten, S, Rivera, VM, Hughes, TP & Branford, S 2016, 'The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib', Blood, vol. 127, no. 15, pp. 1870-1880. Open access
2016	Ross, D, Altamura, H, Hahn, C, Nicola, M, Yeoman, A, Holloway, M, Geoghegan, J, Feng, J, Schreiber, A, Branford, S, Moore, S & Scott, H 2016, 'Delayed diagnosis leading to accelerated-phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene', Leukemia, vol. 30, no. 6, pp. 1402-1405. Open access
2016	Torra, OS, Beppu, L, Smith, JL, Welden, L, Georgievski, J, Gupta, K, Kumar, R, Yeung, CC, Paguirigan, A, Gooley, TA, Branford, S & Radich, JP 2016, 'Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots', Blood, vol. 127, no. 2, pp. 2773-2774. Open access
2016	Yoshida, C, Nakamae, H, Fletcher, L, Koga, D, Sogabe, T, Matsumura, I, Kanakura, Y, Branford, S & Naoe, T 2016, 'Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale', SpringerPlus, vol. 5, no. 569, pp. 1-7. Open access
2015	Enjeti, A, Granter, N, Ashraf, A, Fletcher, L, Branford, S, Rowlings, P & Dooley, S 2015, 'A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system', Pathology, vol. 47, no. 6, pp. 570-574. Open access
2015	Yeung, DT, Osborn, MP, White, DL, Branford, S & Hughes, TP and 18 other authors and 1 consortium 2015, 'TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets', Blood, vol. 125, no. 6, pp. 915-923. Open access
2015	Yeung, DT, Tang, C, Vidovic, L, White, DL, Branford, S, Hughes, TP & Yong, AS 2015, 'KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy', Blood, vol. 126, no. 25, pp. 2720-2723. Open access
2014	Parker, WT, Phillis, SR, Yeung, DT, Hughes, TP, Scott, HS & Branford, S 2014, 'Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination', Blood, vol. 124, no. 1, pp. 153-155.
2012	Parker, WT, Ho, M, Scott, HS, Hughes, TP & Branford, S 2012, 'Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile', Blood. Open access

Conferences

Year	Output
2019	Branford, S & Shanmuganathan, N 2019, 'NGS in CML - new standard diagnostic procedure?', 24th Congress of the European Hematology Association, Wolters Kluwer Health, vol. 3, no. S2, pp. 48-50. Open access
2016	Wang, P, Parker, WT, Branford, S & Schreiber, AW 2016, 'BAM-matcher: a tool for rapid NGS sample matching', 15th European Conference on Computational Biology (ECCB), Oxford University Press, vol. 32, no. 17, pp. 2699-2701. Open access

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Albert Schweitzer Ziekenhuis	NETHERLANDS
ARIAD Pharmaceuticals	UNITED STATES
Austin Hospital	AUSTRALIA
Australasian Leukaemia and Lymphoma Group	AUSTRALIA
Australian National University	AUSTRALIA
Blood Institute	AUSTRALIA
Brabois Hospital	FRANCE
Calvary Mater Hospital	AUSTRALIA
Catholic University of Korea	KOREA, REPUBLIC OF (SOUTH)
Central Adelaide Local Health Network Incorporated	AUSTRALIA
Centre Léon Bérard	FRANCE
Chang Gung University	TAIWAN
Duke-Nus Medical School	SINGAPORE
Ecole Polytechnique Federale de Lausanne	ITALY
Erasmus MC Cancer Institute	NETHERLANDS
Federal University of Minas Gerais	BRAZIL
Federal University of Parana	BRAZIL
Federal University of Rio de Janeiro	BRAZIL
Federal University of the State of Rio de Janeiro	BRAZIL
Finnish Red Cross	FINLAND
Fiona Stanley Hospital	AUSTRALIA
Flinders University	AUSTRALIA
Fred Hutchinson Cancer Center	UNITED STATES
Garvan Institute of Medical Research	AUSTRALIA
Greenslopes Private Hospital	AUSTRALIA
Hammersmith Hospital	UNITED KINGDOM
Helsinki University Hospital	FINLAND
Hopital Saint-Louis	FRANCE
Howard Hughes Medical Institute	UNITED STATES
Hudson Institute of Medical Research	AUSTRALIA
Icon Cancer Care	AUSTRALIA
Imperial College of Science, Technology and Medicine	UNITED KINGDOM
John Hunter Hospital	AUSTRALIA
Johns Hopkins University	UNITED STATES
Kinki University	JAPAN
Kyoto University	JAPAN
Linkou Chang Gung Memorial Hospital	TAIWAN
Liverpool Hospital Elizabeth	AUSTRALIA
Massuchusetts General Hospital	UNITED STATES
Mater Medical Centre	AUSTRALIA
Mater Pathology	AUSTRALIA
Mayo Clinic	UNITED STATES
McMaster University	CANADA
Memorial Sloan-Kettering Cancer Center	UNITED STATES
Mito Medical Centre	JAPAN
Monash University	AUSTRALIA
Nagoya Medical Centre	JAPAN
Nambour General Hospital	AUSTRALIA
National Cancer Centre Singapore	SINGAPORE
Nepean Hospital	AUSTRALIA
New Jersey City University	UNITED STATES
Newcastle University, United Kingdom	UNITED KINGDOM
NHS Foundation Trust	UNITED KINGDOM
Novartis (Australia)	AUSTRALIA
Novartis (United Kingdom)	UNITED KINGDOM
Novartis Healthcare	UNITED STATES
Novartis Institutes for Biomedical Research	UNITED STATES
Novartis Pharma AG Switzerland	SWITZERLAND
Novartis Pharmaceuticals	UNITED STATES
Oregon Health and Science University	UNITED STATES
Osaka City University	JAPAN
Osaka University	JAPAN
Otsuka Pharmaceutical	JAPAN
Peter MacCallum Cancer Centre	AUSTRALIA
Princess Margaret Hospital for Children	AUSTRALIA
Queensland Institute of Medical Research	AUSTRALIA
Royal Adelaide Hospital	AUSTRALIA
Royal Brisbane and Women's Hospital	AUSTRALIA
Royal North Shore Hospital	AUSTRALIA
SA Pathology	AUSTRALIA
Singapore General Hospital	SINGAPORE
Sir Charles Gardiner Hospital	AUSTRALIA
South Australian Health and Medical and Research Institute (SAHMRI)	AUSTRALIA
South Australian Health and Medical Institute	AUSTRALIA
St Vincents Hospital	UNITED STATES
Stanford University	UNITED STATES
Statistical Revelations	AUSTRALIA
Texas Tech University Health Sciences Center	UNITED STATES
The Alfred Hospital	AUSTRALIA
The Queen Elizabeth Hospital	AUSTRALIA
Toronto General Hospital	CANADA
Universidade de Sao Paulo - USP	BRAZIL
Universitätsklinikum Jena	GERMANY
Universite Victor Segalen	FRANCE
University Hospital, Bordeaux	FRANCE
University of Adelaide	AUSTRALIA
University of Barcelona	SPAIN
University of Bologna	ITALY
University of Bordeaux	FRANCE
University of California San Francisco	UNITED STATES
University of Chicago	UNITED STATES
University of Helsinki	FINLAND
University of Jena	GERMANY
University of Massachusetts Medical School	UNITED STATES
University of Milano-Bicocca	ITALY
University of New South Wales	AUSTRALIA
University of Newcastle	AUSTRALIA
University Of Paris Sud (Paris 11)	FRANCE
University of Poitiers	FRANCE
University of Queensland	AUSTRALIA
University of Sao Paulo	BRAZIL
University of South Australia	AUSTRALIA
University of Southampton	UNITED KINGDOM
University of Sydney	AUSTRALIA
University of Texas	UNITED STATES
University of Texas MD Anderson Cancer Centre	UNITED STATES
University of Toronto	CANADA
University of Turku	FINLAND
University of Utah	UNITED STATES
University of Washington	UNITED STATES
University of Western Australia	AUSTRALIA
VU University Medical Center	NETHERLANDS

Teaching & student supervision

Research degree supervision

Supervisions from 2010 shown

Thesis title	Student status
Enhanced bioinformatics for improved risk stratification and outcome prediction in chronic myeloid leukaemia (CML)	Current
Precision medicine in chronic myeloid leukaemia	Completed

more less

Professor Susan Branford

About me

About me

Centre for Cancer Biology

About me

Professional Associations

Experience

Qualifications

Research

Research focus

Projects

Outputs

Chapters

Journal Articles

Conferences

External engagement & recognition

Collaborations

Collaborations

Teaching & student supervision

Courses and programs

Research degree supervision

Gallery